News Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
4.67 ^USD	+0.43%		-8.43%	-9.14%

Apr. 01	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	CI
Feb. 13	Transcript : Vistagen Therapeutics, Inc., Q3 2024 Earnings Call, Feb 13, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vistagen to Present at the 2024 Anxiety and Depression Association Conference	Apr. 10	AQ
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference	Apr. 09	BU
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01	BU
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01	CI
Vistagen to Present at Stifel 2024 Virtual CNS Days	Mar. 11	BU
Vistagen to Present at TD Cowen 44th Annual Health Care Conference	Feb. 28	BU
Transcript : Vistagen Therapeutics, Inc., Q3 2024 Earnings Call, Feb 13, 2024	Feb. 13
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	Feb. 13	MT
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update	Feb. 13	BU
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024	Feb. 06	BU
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	Dec. 27	MT
Vistagen	Dec. 27	MT
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27	BU
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27	CI
North American Morning Briefing : Futures Pause -2-	Dec. 08	DJ
Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6	Dec. 07	MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target	Nov. 14	MT
Transcript : Vistagen Therapeutics, Inc., Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Summary

Filters